NURS6521 ADVANCED PHARMACOLOGY MIDTERM EXAM
– ACTUAL EXAM PRACTICE QUESTIONS AND 100%
VERIFIED CORRECT ANSWERS | COMPLETE EXAM PREP
TESTBANK | GUARANTEED PASS | INSTANT DOWNLOAD
PDF
ore Domains
C
Pharmacokinetics and Pharmacodynamics
Advanced Physiology and Pathophysiology
Neurological and Musculoskeletal Pharmacology
Cardiovascular and Renal Pharmacology
Endocrine and Reproductive Pharmacology
Antibiotic Stewardship and Antimicrobial Therapy
Pediatric and Geriatric Prescribing Considerations
Ethical and Legal Prescribing Practices
I ntroduction
This comprehensive practice assessment is designed to evaluate advanced
nursing students' proficiency in clinical pharmacology. The exam assesses the
ability to integrate physiological principles with therapeutic drug
management across the lifespan. Through a combination of foundational
theory and complex, scenario-based questions, candidates must demonstrate
professional decision-making and problem-solving skills. The focus remains
on the safe application of pharmacotherapeutics, regulatory compliance, and
evidence-based practice. Successful completion indicates a mastery of drug
mechanisms, adverse effect profiles, and the clinical judgment necessary for
an advanced practice nurse to prescribe safely and effectively in diverse
healthcare settings.
SECTION 1: QUESTIONS
, 68-year-old male with a history of chronic kidney disease (CKD) is
A
prescribed a new medication that is primarily excreted renally. Which
pharmacokinetic process is most likely to be impaired in this patient?
A. Absorption
B. Distribution
C. Metabolism
🔴
D. Excretion
🔵
Explanation: Excretion is the process by which drugs are removed from
the body, primarily via the kidneys; impaired renal function directly reduces
the clearance of drugs excreted through this route.
hen prescribing a prodrug to a patient with known hepatic impairment, the
W
Advanced Practice Nurse (APN) understands that:
A. The drug will reach toxic levels faster.
🔴
B. The drug may have decreased therapeutic efficacy.
C. The drug will bypass first-pass metabolism.
D. Renal excretion will increase to compensate.
🔵
Explanation: Prodrugs require metabolic conversion in the liver to
become active; therefore, hepatic impairment can lead to lower levels of the
active metabolite.
hich term describes the range between the minimum effective
W
concentration and the toxic concentration of a drug?
A. Bioavailability
🔴
B. Therapeutic index
C. Half-life
D. Steady state
🔵
Explanation: The therapeutic index (or window) represents the safety
margin of a drug, indicating the range of plasma concentrations where the
drug is effective without being toxic.
, n 82-year-old female is starting a new medication with a high
A
protein-binding affinity. Her serum albumin is low. The APN expects:
🔴
A. An increased risk of drug toxicity.
B. A decreased volume of distribution.
C. A need for a higher loading dose.
D. Faster renal clearance of the drug.
🔵
Explanation: When albumin is low, there are fewer binding sites, leading
to an increase in the "free" or active fraction of the drug, which increases the
risk of toxicity.
patient is taking a drug that is a known inducer of the CYP3A4 enzyme
A
system. If a second drug metabolized by the same system is added, the APN
expects:
A. Increased levels of the second drug.
🔴
B. Decreased levels of the second drug.
C. No change in drug concentrations.
D. Increased renal toxicity of the first drug.
🔵
Explanation: Enzyme inducers increase the rate of metabolism of
substrate drugs, leading to lower plasma concentrations and potentially
reduced efficacy.
hich of the following describes an idiosyncratic drug reaction?
W
A. A predictable side effect based on dosage.
B. An allergic reaction mediated by IgE.
🔴
C. An unpredictable, genetically determined response.
D. A secondary effect that occurs after long-term use.
🔵
Explanation: Idiosyncratic reactions are rare, unpredictable, and often
linked to individual genetic differences rather than the drug's known
mechanism of action.
patient is prescribed a medication with a half-life of 12 hours. How long
A
will it take for the drug to reach steady state?
, . 12 to 24 hours
A
B. 24 to 36 hours
🔴
C. 48 to 60 hours
D. 72 to 96 hours
🔵
Explanation: Steady state is generally reached after approximately 4 to 5
half-lives (12 hours x 4 or 5 = 48–60 hours).
hich pregnancy category (based on older FDA labeling still widely
W
referenced) indicates that animal studies show no risk, but there are no
adequate studies in humans?
A. Category A
🔴
B. Category B
C. Category C
D. Category X
🔵
Explanation: Category B indicates that animal reproduction studies have
failed to demonstrate a risk to the fetus and there are no adequate and
well-controlled studies in pregnant women.
patient with myasthenia gravis is prescribed neostigmine. This drug works
A
by:
🔴
A. Inhibiting acetylcholinesterase.
B. Blocking muscarinic receptors.
C. Stimulating beta-2 receptors.
D. Increasing norepinephrine release.
🔵
Explanation: Neostigmine is an anticholinesterase agent that prevents the
breakdown of acetylcholine, thereby increasing its availability at the
neuromuscular junction.
hen educating a patient on the use of an anticholinergic medication, which
W
side effect should the APN include?
A. Excessive salivation
B. Diarrhea
– ACTUAL EXAM PRACTICE QUESTIONS AND 100%
VERIFIED CORRECT ANSWERS | COMPLETE EXAM PREP
TESTBANK | GUARANTEED PASS | INSTANT DOWNLOAD
PDF
ore Domains
C
Pharmacokinetics and Pharmacodynamics
Advanced Physiology and Pathophysiology
Neurological and Musculoskeletal Pharmacology
Cardiovascular and Renal Pharmacology
Endocrine and Reproductive Pharmacology
Antibiotic Stewardship and Antimicrobial Therapy
Pediatric and Geriatric Prescribing Considerations
Ethical and Legal Prescribing Practices
I ntroduction
This comprehensive practice assessment is designed to evaluate advanced
nursing students' proficiency in clinical pharmacology. The exam assesses the
ability to integrate physiological principles with therapeutic drug
management across the lifespan. Through a combination of foundational
theory and complex, scenario-based questions, candidates must demonstrate
professional decision-making and problem-solving skills. The focus remains
on the safe application of pharmacotherapeutics, regulatory compliance, and
evidence-based practice. Successful completion indicates a mastery of drug
mechanisms, adverse effect profiles, and the clinical judgment necessary for
an advanced practice nurse to prescribe safely and effectively in diverse
healthcare settings.
SECTION 1: QUESTIONS
, 68-year-old male with a history of chronic kidney disease (CKD) is
A
prescribed a new medication that is primarily excreted renally. Which
pharmacokinetic process is most likely to be impaired in this patient?
A. Absorption
B. Distribution
C. Metabolism
🔴
D. Excretion
🔵
Explanation: Excretion is the process by which drugs are removed from
the body, primarily via the kidneys; impaired renal function directly reduces
the clearance of drugs excreted through this route.
hen prescribing a prodrug to a patient with known hepatic impairment, the
W
Advanced Practice Nurse (APN) understands that:
A. The drug will reach toxic levels faster.
🔴
B. The drug may have decreased therapeutic efficacy.
C. The drug will bypass first-pass metabolism.
D. Renal excretion will increase to compensate.
🔵
Explanation: Prodrugs require metabolic conversion in the liver to
become active; therefore, hepatic impairment can lead to lower levels of the
active metabolite.
hich term describes the range between the minimum effective
W
concentration and the toxic concentration of a drug?
A. Bioavailability
🔴
B. Therapeutic index
C. Half-life
D. Steady state
🔵
Explanation: The therapeutic index (or window) represents the safety
margin of a drug, indicating the range of plasma concentrations where the
drug is effective without being toxic.
, n 82-year-old female is starting a new medication with a high
A
protein-binding affinity. Her serum albumin is low. The APN expects:
🔴
A. An increased risk of drug toxicity.
B. A decreased volume of distribution.
C. A need for a higher loading dose.
D. Faster renal clearance of the drug.
🔵
Explanation: When albumin is low, there are fewer binding sites, leading
to an increase in the "free" or active fraction of the drug, which increases the
risk of toxicity.
patient is taking a drug that is a known inducer of the CYP3A4 enzyme
A
system. If a second drug metabolized by the same system is added, the APN
expects:
A. Increased levels of the second drug.
🔴
B. Decreased levels of the second drug.
C. No change in drug concentrations.
D. Increased renal toxicity of the first drug.
🔵
Explanation: Enzyme inducers increase the rate of metabolism of
substrate drugs, leading to lower plasma concentrations and potentially
reduced efficacy.
hich of the following describes an idiosyncratic drug reaction?
W
A. A predictable side effect based on dosage.
B. An allergic reaction mediated by IgE.
🔴
C. An unpredictable, genetically determined response.
D. A secondary effect that occurs after long-term use.
🔵
Explanation: Idiosyncratic reactions are rare, unpredictable, and often
linked to individual genetic differences rather than the drug's known
mechanism of action.
patient is prescribed a medication with a half-life of 12 hours. How long
A
will it take for the drug to reach steady state?
, . 12 to 24 hours
A
B. 24 to 36 hours
🔴
C. 48 to 60 hours
D. 72 to 96 hours
🔵
Explanation: Steady state is generally reached after approximately 4 to 5
half-lives (12 hours x 4 or 5 = 48–60 hours).
hich pregnancy category (based on older FDA labeling still widely
W
referenced) indicates that animal studies show no risk, but there are no
adequate studies in humans?
A. Category A
🔴
B. Category B
C. Category C
D. Category X
🔵
Explanation: Category B indicates that animal reproduction studies have
failed to demonstrate a risk to the fetus and there are no adequate and
well-controlled studies in pregnant women.
patient with myasthenia gravis is prescribed neostigmine. This drug works
A
by:
🔴
A. Inhibiting acetylcholinesterase.
B. Blocking muscarinic receptors.
C. Stimulating beta-2 receptors.
D. Increasing norepinephrine release.
🔵
Explanation: Neostigmine is an anticholinesterase agent that prevents the
breakdown of acetylcholine, thereby increasing its availability at the
neuromuscular junction.
hen educating a patient on the use of an anticholinergic medication, which
W
side effect should the APN include?
A. Excessive salivation
B. Diarrhea
